Diabetes is a metabolic disease, wherein
the body is either unable to secret insulin (type 1 diabetes) or is
unable to utilize the generated insulin (type 2 diabetes). This elevated
sugar level leads to various symptoms such as increased thirst &
appetite, weight loss, frequent urination, fatigue, cuts and bruises
that do not heal, numbness and tingling in hands and feet. If untreated,
diabetes leads to various acute and chronic life-threatening
complications. Approximately 90% of all cases of diabetes worldwide are
type 2 diabetes mellitus. Diabetes occurs at any age; however, it is
more common in adults aged 60 and above. Diabetes affects 1 in 4 people
over the age of 65. People who are overweight, older, or suffering from
some other diseases such as pancreatic disorders or high blood pressure
are at a higher risk of developing diabetes. As of 2016, diabetes is the
seventh leading cause of death. An estimated 415 million people are
suffering with diabetes globally. The figure is expected to rise to 642
million by 2040.
Report Overview @ https://www.transparencymarketresearch.com/non-insulin-anti-diabetes-drugs-market.html
Based on drug class, the non-insulin
anti-diabetes drugs market has been segmented into GLP-1 receptor
agonists (dulaglutide, exenatide), amylin analogue (pramlintide),
sulphonylureas (tolbutamide, glimepiride), biguanides (metformin),
alpha-glucosidase inhibitors (acarbose), DPP-4 inhibitors (alogliptin),
and SGLT-2 inhibitors (canagliflozin, dapagliflozin). The SGLT-2
inhibitors segment is expected to witness strong growth due to minimal
side effects and more efficacy as monotherapy as well as combination
therapy. Extensive research is being carried out on SGLT2 inhibitors to
develop newer and more efficient molecules belonging to this class.
Currently, Novartis’ LIK066, Ionis Pharmaceuticals’ ISIS 388626, and
Jiangsu Hengrui Medicine Co.’s henagliflozin (SHR-3824) are the major
pipeline SGLT-2 inhibitors under clinical studies expected to be
launched during the forecast period from 2017 to 2025. In terms of
dosage form, the non-insulin anti-diabetes drugs market has been
segmented into oral and injectable. The injectable non-insulin
anti-diabetes drugs segment is expected to experience significant growth
during the forecast period due to factors such as few side effects, no
impact on weight of a patient, effectiveness in combination with other
anti-diabetes drugs, and strong R&D activities to develop newer
products. Currently, Eli Lilly and Company’s LY 3298176, Janssen
Pharmaceuticals’ JNJ 54728518, and Sanofi’s SAR 425899 are the major
pipeline injectable molecules under clinical development. Major factors
that contribute to the growth of the non-insulin anti-diabetes drugs
market include rapid rise in prevalence of diabetes across the globe,
extensive R&D activities, and rising demand for economical and
long-acting drugs. However, expiration of patents of various blockbuster
drugs during the forecast period is the major restraint of the market.
In terms of geography, the non-insulin
anti-diabetes drugs market can be classified into North America, Latin
America, Europe, Asia Pacific, and Middle East & Africa. North
America dominates the non-insulin anti-diabetes drugs market, followed
by Europe, due to the higher incidence and prevalence rates, large
number of ongoing clinical trials, and availability of improved
treatment options and health care infrastructure. Asia Pacific is an
emerging market for non-insulin anti-diabetes drugs due to increasing
prevalence of type 2 diabetes, gradual development of medical
infrastructure, and rising awareness. However, high cost of therapy,
lack of availability of treatment options, and poor patient awareness
are factors restraining the non-insulin anti-diabetes drugs market in
regions such as Middle East & Africa and Latin America.
Major players operating in the
non-insulin anti-diabetes drugs market include Sanofi, Abbott
Laboratories, Inc., AstraZeneca plc, Eli Lilly and Company, F. Hoffmann
La-Roche Lt
No comments:
Post a Comment